Merck announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee “agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.” Peter S. Kim, Ph.D., executive vice president, and president of Merck Research Laboratories, said, “Merck has been committed to pursuing the use of GARDASIL in both males and females since the vaccine was discovered over a decade ago. We are pleased that the Advisory Committee agrees that the data support the use of GARDASIL in boys and men.”

http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20090909006540&newsLang=en